Mankind Pharma Limited
MANKIND · Pharma · NSE
₹2,376
Current Market Price
Fair Value (DCF)
₹1,051
Discount to FV
-55.8%
Updated just now
YieldIQ Score
40/100
Piotroski F-Score
5/9
Economic Moat
Narrow
Confidence
43%
ROE
11.7%
Debt/Equity
0.39
WACC
9.5%
Market Cap
₹98,115 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
17.1%
Return on capital employed
EV / EBITDA
29.4×
Enterprise multiple
Debt / EBITDA
2.4×
Leverage vs earnings
Interest Coverage
7.0×
EBIT covers interest
Current Ratio
1.23×
Short-term liquidity
Asset Turnover
0.49×
Revenue per ₹ of assets
Revenue CAGR (3Y)
9.2%
3-year revenue growth
Revenue CAGR (5Y)
11.4%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹2,376.2
Bear case
Discount -296.7%
Base case
Discount -126.0%
Bull case
Discount -63.2%
Ratio Trends
MANKIND · last 5 annual periods
ROE
11.7%
ROCE
17.1%
Operating Margin
—
Debt / Equity
0.39×
PE
—
EV / EBITDA
—
Historical Financials
MANKIND · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 yfinance | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹7782 Cr | ₹8749 Cr | ₹10.3K Cr | ₹12.2K Cr | ₹14.3K Cr | +16.4% |
| EBITDA | ₹2197 Cr | ₹2037 Cr | ₹2824 Cr | ₹3567 Cr | ₹3858 Cr | +15.1% |
| EBIT | — | ₹1703 Cr | ₹2418 Cr | — | — | +9.2% |
| PAT | ₹1433 Cr | ₹1282 Cr | ₹1913 Cr | ₹1991 Cr | ₹1913 Cr | +7.5% |
| EPS (diluted) | — | ₹32.00 | ₹47.68 | — | — | +10.5% |
| CFO | ₹920 Cr | ₹1813 Cr | ₹2152 Cr | ₹2413 Cr | ₹3121 Cr | +35.7% |
| CapEx | ₹-2346 Cr | ₹-832 Cr | ₹-389 Cr | ₹-520 Cr | ₹-737 Cr | — |
| FCF | ₹-1426 Cr | ₹981 Cr | ₹1763 Cr | ₹1893 Cr | ₹2384 Cr | — |
| Total Assets | ₹9148 Cr | ₹9715 Cr | ₹12.0K Cr | ₹27.8K Cr | ₹28.1K Cr | +32.4% |
| Total Debt | ₹873 Cr | ₹170 Cr | ₹207 Cr | ₹8511 Cr | ₹6312 Cr | +64.0% |
| Shareholders' Equity | ₹6155 Cr | ₹7435 Cr | ₹9363 Cr | ₹14.3K Cr | ₹16.3K Cr | +27.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
MANKIND vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 ZYDUSLIFE ZYDUSLIFE | — | — | Pending | 17.2% | — |
 AUROPHARMA AUROPHARMA | — | — | Pending | 9.2% | 21.4× |
 CIPLA CIPLA | — | — | Pending | 11.3% | 25.5× |
 DRREDDY DRREDDY | — | — | Pending | 11.4% | 24.4× |
 LUPIN LUPIN | — | — | Pending | 23.8% | 19.8× |
Click a ticker to view its fair-value analysis.
Dividend History
1 ex-dividend event on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹1.00/sh
Last payout
2025-08-08
₹1.00
Peak payout
₹1.00
Trailing yield
0.04%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Mankind Pharma Limited (MANKIND.NS) trades at 2376.20 vs a model fair value of 1051.43, a gap of -55.8%. Piotroski F-score: 5/9. Moat lab...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of MANKIND →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for MANKIND →
Compare
Head-to-head with peers
Compare MANKIND side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse MANKINDNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.